Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Delisting risk
confidence 98%
filed 2026-09-21
EX-99.1
Gauzy received a delisting notification from Nasdaq dated September 15, 2026, determining to delist the Company's securities from the Nasdaq Global Market due to two failures: (1) bid price below $1 per share for 30 consecutive business days, violating Listing Rule 5450(a)(1), and (2) failure to file its Form 20-F for the year ended December 31, 2025, violating Listing Rule 5250(c)(1). The Company intends to appeal the determination, which will stay delisting pending the appeal hearing, but the press release explicitly states "There can be no assurance that upon the Appeal hearing, the Panel will determine to allow the continued listing." This is a material delisting risk disclosure under Item 3.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-09-21
Item 8.01
BioCardia disclosed receipt of a Nasdaq deficiency notice on August 19, 2026, for failure to maintain the $1.00 minimum bid price requirement, followed by notification on September 21, 2026, that the company regained compliance after 10 consecutive business days at or above $1.00. While the immediate delisting risk has been resolved, the disclosure centers on the company's listing status and the explicit caveat that "there can be no assurance that the Company will be able to maintain compliance with the Minimum Bid Price Requirement in the future," which is material to investors assessing the registrant's continued trading status.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-09-21
EX-99.43
CordovaCann announced a delay in filing its annual financial statements for the fiscal year ended June 30, 2019, and explicitly stated that a failure-to-file cease trade order will be issued by securities regulators. The delay stems from a change in accounting treatment of Oregon investments required by auditors.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-09-21
EX-99.1
The press release announces that Nasdaq has stated it will delist Davis Commodities' Class A ordinary shares, with trading already suspended since March 25, 2026. Nasdaq will file a Form 25 with the SEC to complete the delisting, which becomes effective ten days after filing. This is a material delisting event that directly affects the registrant's listing status and investor access to trading, even though shares will continue trading on OTC Markets.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 98%
filed 2026-09-15
EX-99.1
Nasdaq notified Instinct Bio on September 9–10, 2026 that the Company failed three continued listing requirements: minimum market value of listed securities (MVLS) below $50M, minimum market value of publicly held shares (MVPHS) below $15M, and minimum bid price below $1.00 per share. The Company has 180 calendar days to regain compliance or face delisting, with the option to appeal or transfer to Nasdaq Capital Market. This is a classic delisting-risk disclosure under Item 3.01 equivalent, materially threatening the Company's continued listing status.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 98%
filed 2026-09-15
EX-99.1
Baosheng received a Nasdaq deficiency notice on September 10, 2026, for failure to maintain the minimum bid price of $1.00 per share required under Nasdaq Listing Rule 5550(a)(2). The company has 180 calendar days (until March 9, 2027) to regain compliance or face potential delisting. This is a classic delisting-risk disclosure under Item 3.01 equivalent, as it directly threatens the company's continued listing status on Nasdaq Capital Market.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-09-15
Item 3.01
zSpace voluntarily notified Nasdaq of its intention to withdraw its common stock from listing on The Nasdaq Capital Market and deregister under Section 12(b) of the Exchange Act. Trading has been suspended since April 28, 2026, following a Nasdaq delisting determination on April 21, 2026, and the company's appeal was denied on August 6, 2026. Delisting is expected to become effective October 5, 2026, with deregistration on December 24, 2026.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-09-15
EX-99.1
Electra received notice from Nasdaq that it has failed to meet the $1.00 minimum bid price requirement for continued listing and has been granted a 180-calendar-day extension (until March 15, 2027) to regain compliance. This is a classic delisting-risk disclosure: the company is out of compliance with a continued listing standard and faces potential delisting if it cannot cure the deficiency within the extension period. The press release explicitly states the company must achieve a closing bid price at or above US$1.00 for 10 consecutive business days to regain compliance, and notes there is no assurance it will do so.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 85%
filed 2026-09-15
Item 3.03
Jaguar Health implemented a 1-for-15 reverse stock split effective September 17, 2026, undertaken to support compliance with Nasdaq's continued listing standards. The reverse split represents a corrective action to address prior non-compliance with Nasdaq listing requirements.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-09-15
Item 8.01
Profusa received a Nasdaq Compliance Determination Letter confirming current compliance with the Bid Price Rule and Equity Rule, but is now subject to a one-year Mandatory Panel Monitor period. Critically, if the Company fails to satisfy the Equity Rule during this monitoring period, Nasdaq will issue a delisting determination without allowing a compliance plan or cure period—a material escalation of delisting risk. This disclosure directly addresses the consequences of non-compliance and the heightened threat of delisting, making it a delisting_risk event under Item 8.01.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-09-15
EX-99.1
The press release announces a 25-for-1 reverse share split effective September 17, 2026, explicitly undertaken "in order to regain compliance with the minimum $1.00 bid price per share requirement of Nasdaq's Marketplace Rule 5550(a)(2)." This is a direct response to a delisting risk — the Company was non-compliant with Nasdaq's continued listing standards and took corrective action to avoid delisting. While the reverse split itself is the disclosed action, the underlying trigger and materiality stem from the delisting compliance issue.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-09-15
Item 3.01
SOBR Safe received a delisting notice from Nasdaq on September 14, 2026, effective September 16, 2026, due to failure to maintain the minimum $1.00 bid price requirement and stockholders' equity of $2,500,000 under Nasdaq Listing Rules 5550(a)(2) and 5550(b)(1). The company's common stock will be removed from the Nasdaq Capital Market and transferred to OTC Markets quotation, representing a material change in trading venue and liquidity that directly affects investor access and valuation.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-09-15
XMax Inc. received a notification letter from Nasdaq on September 10, 2026, indicating non-compliance with Listing Rule 5635(d) due to issuance of greater than 20% of outstanding shares at prices below the Minimum Price without prior shareholder approval. The company has 45 calendar days to submit a compliance plan or face potential delisting proceedings, with the possibility of a hearing before a Nasdaq Hearings Panel if the plan is rejected. This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 94%
filed 2026-09-15
Item 3.01
Origin Bancorp voluntarily withdrew its NYSE listing and transferred its principal stock exchange listing to the Texas Stock Exchange, effective October 13, 2026. This material change in listing venue affects investor access and trading mechanics for the company's common stock.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 90%
filed 2026-09-14
Item 3.01
Texas Capital Bancshares voluntarily notified Nasdaq of its intention to withdraw its common and preferred stock listings from Nasdaq and transfer them to the Texas Stock Exchange, effective October 7-8, 2026, with ticker symbol changes on November 9, 2026. While voluntary rather than involuntary, this transfer of primary listing from a major national exchange to a regional exchange materially affects trading liquidity, market access, and investor capital markets access.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-09-14
Item 3.01
SmartKem received formal notice from Nasdaq on March 5, 2026 for non-compliance with the minimum bid price requirement ($1.00 per share under Listing Rule 5550(a)(2)). Although the company subsequently regained compliance by September 10, 2026 after maintaining the minimum bid price for 13 consecutive business days, the disclosure of the initial delisting notice and the compliance remediation process is a material delisting-risk event that would affect investor assessment of the registrant's listing status and stock price stability.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-09-14
Item 8.01
The filing discloses Longeveron's receipt of a Nasdaq notice on September 11, 2026, confirming that the Company has regained compliance with the $1.00 minimum bid price requirement after previously falling below it for thirty consecutive business days. While the resolution is positive (compliance regained), the disclosure documents the delisting risk event and its cure. This is material because it directly addresses the registrant's continued listing status on Nasdaq Capital Market, a matter that would significantly affect investor assessment of the company's trading and capital-raising prospects.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-09-14
Item 8.01
The filing discloses that Boxlight regained compliance with Nasdaq's minimum stockholders' equity rule (Rule 5550(b)(1)) after a hearing, but the Panel imposed a one-year Discretionary Panel Monitor with severe consequences: any future non-compliance will result in immediate delisting without opportunity for a compliance plan or cure period. This is a material delisting-risk disclosure because it documents the company's prior non-compliance, conditional continued listing status, and heightened vulnerability to delisting if it fails to maintain compliance during the monitoring period.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 85%
filed 2026-09-14
Celularity disclosed that it has regained compliance with two Nasdaq listing requirements (minimum bid price and minimum market value of listed securities) after previously being deficient, but notably still remains non-compliant with Nasdaq Listing Rule 5250(c)(1) regarding delayed periodic report filings. The disclosure of ongoing delisting risk and the company's efforts to regain compliance with Nasdaq's periodic reporting requirement directly implicates continued listing status, which is material to investors.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-09-14
Item 3.01 discloses that InnSuites received notice from NYSE American on September 10, 2026 that the Trust is not currently in compliance with continued listing standards but has been granted an 18-month cure period through December 24, 2027. The filing explicitly states that if the Trust fails to achieve compliance by the deadline or does not make adequate progress, "NYSE Regulation staff could initiate delisting proceedings." This is a classic delisting-risk disclosure under Item 3.01, materially affecting investor assessment of the registrant's continued public trading status.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-09-14
EX-99.1
Waldencast has announced its Board-approved decision to voluntarily delist its Class A Ordinary Shares and Warrants from Nasdaq and deregister under the Exchange Act, with Form 25 filing expected September 24, 2026 and last trading day October 2, 2026. This is a material delisting event that fundamentally alters the registrant's public market status and investor access, directly triggering Item 3.01 disclosure obligations.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-09-11
Item 8.01
The Company received a deficiency notice from OTC Markets Group on June 6, 2026, for failing to maintain a minimum closing bid price of $0.01 for 30 consecutive calendar days, with an initial compliance cure deadline of October 5, 2026; management is pursuing the reverse stock split to address the bid price requirement and avoid downgrade to OTC Pink Open Market.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-09-11
Item 3.01
Following the merger consummation, AtaiBeckley Inc. notified Nasdaq of the transaction and requested suspension of trading and delisting of its Common Stock via Form 25, with intent to file Form 15 to terminate registration and reporting obligations.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-09-11
The filing discloses that on August 26, 2026, NYSE notified Natuzzi of a determination to commence delisting proceedings due to failure to maintain the required minimum average global market capitalization of US$15 million over a consecutive 30 trading-day period under NYSE Listed Company Manual Section 802.01B. The Company filed a request for review on September 10, 2026, which will be scheduled for at least 25 business days later. This is a material delisting risk disclosure under Item 3.01 equivalent for a foreign private issuer.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-09-11
Item 3.01
Fractyl Health received a delisting notice from Nasdaq on September 10, 2026, after failing to maintain the minimum bid price of $1.00 per share for 30 consecutive business days and not regaining compliance within the 180-day grace period. The company intends to request a hearing before a Nasdaq Hearings Panel to stay delisting, and has filed a proxy statement seeking stockholder approval for a reverse stock split to regain compliance. This is a clear and material delisting risk disclosure under Item 3.01.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-09-11
EX-99.1
The press release announces a 5-for-1 share consolidation effective September 15, 2026, explicitly stating "The objective of the share consolidation is to enable the Company to regain compliance with Nasdaq Marketplace Rule 5550(a)(2) and maintain its listing on Nasdaq." This disclosure reveals the Company was out of compliance with Nasdaq's minimum bid price rule and faced delisting risk, which is material to investors assessing the registrant's continued listing status and financial health.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-09-11
Item 3.01
Greenland Technologies received notice from Nasdaq on September 10, 2026, that it has failed to meet the minimum bid price requirement (closing bid below $1.00 for 30 consecutive business days) and has been granted a second 180-day compliance period until March 8, 2027, to regain compliance or face delisting. The disclosure explicitly states that if compliance is not achieved by the Compliance Date, the Company's Class A Ordinary Shares are subject to delisting, with only the possibility of appeal. This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-09-11
EX-99.1
The Company received a formal NYSE notice that it is below compliance standards due to Class A ordinary shares trading below US$1.00 over a consecutive 30 trading-day period. Under NYSE Section 802.01C, the Company has a six-month cure period; failure to achieve both a US$1.00 closing price and US$1.00 average closing price by the end of the cure period will trigger NYSE suspension and delisting procedures. This is a material delisting risk disclosure.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-09-11
The 6-K discloses receipt of a non-compliance notification from the NYSE on August 13, 2026, stating that CSN's ADSs failed to maintain the minimum $1.00 average closing price over a consecutive 30-trading-day period, triggering a six-month cure period under NYSE Listed Company Manual Section 802.01C. This is a classic delisting-risk disclosure under Item 3.01 equivalent, as it notifies shareholders of the company's failure to satisfy a continued listing standard and the risk of delisting if compliance is not regained within the specified cure period.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-09-11
EX-99.1
Ferrovial announces that as of 11 September 2026, the delisting of its ordinary shares from Euronext Amsterdam has become effective and trading has ceased. This is a completed delisting event — the effectiveness of the delisting from a major European exchange. Although the company remains listed on Spanish Stock Exchanges and Nasdaq, the removal from Euronext Amsterdam is a material change in listing status that would affect investor access and trading liquidity.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-09-11
EX-99.1
Eastern International received a Nasdaq notification on September 10, 2026, that it has failed to meet the minimum bid price requirement of $1.00 per share for 30 consecutive trading days. The Company has 180 calendar days (until March 9, 2027) to regain compliance or face potential delisting. This is a classic delisting-risk disclosure under the taxonomy, as it directly addresses failure to satisfy a continued listing rule and the threat of delisting if compliance is not achieved.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-09-11
Brightline Interactive received a Staff Determination from Nasdaq on September 11, 2026, delisting the company's common stock due to failure to maintain the minimum bid price of $1.00 per share required by Nasdaq Listing Rule 5550(a)(2). The company did not regain compliance by the September 9, 2026 deadline and plans to appeal the determination. This is a clear delisting notice under Item 3.01, materially threatening the company's continued listing status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 82%
filed 2026-09-11
Item 5.03
Gossamer Bio implemented a 1-for-80 reverse stock split effective September 10, 2026, to regain compliance with Nasdaq's $1.00 minimum bid price requirement by October 5, 2026. The company disclosed substantial doubt about achieving compliance and warned that there is no assurance the common stock will remain listed on the Nasdaq Global Select Market.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-09-10
Item 3.01
The filing discloses a voluntary delisting and liquidation of the Bitwise Dogecoin ETF. Item 3.01 explicitly states that "Bitwise Investment Advisers, LLC, the sponsor of Bitwise Dogecoin ETF (the 'Fund') notified the NYSE Arca, Inc. ('NYSE') of its decision to voluntarily close, de-list and liquidate the Fund" with trading halting on October 15, 2026, and liquidation completing by October 22, 2026. This is a material event affecting all shareholders who will have their shares redeemed for cash at net asset value.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-09-10
Item 3.01
The filing discloses two separate Nasdaq compliance failures: (1) failure to maintain the $1.00 minimum bid price requirement under Listing Rule 5550(a)(2), with a 180-calendar day compliance period ending January 13, 2027, and (2) failure to maintain the $2,500,000 stockholders' equity requirement under Listing Rule 5550(b)(1), with a 45-calendar day plan submission deadline. The Company explicitly states that if it does not regain compliance within the allotted periods, "Nasdaq will provide notice that the Company's common stock will be subject to delisting." This is a direct delisting risk disclosure under Item 3.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-09-10
Item 3.01
iSpecimen received a Nasdaq deficiency letter on September 8, 2026, notifying the company it failed to comply with Nasdaq Listing Rule 5550(b) regarding minimum stockholders' equity of $2.5 million. Nasdaq granted an extension until November 25, 2026 to regain compliance, with explicit warning that failure to evidence compliance by that date or in the year-end periodic report may result in delisting. This is a direct notice of delisting risk under Item 3.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-09-10
Item 3.01
Energy Transfer LP voluntarily transferred its common units and Series I Preferred Units from NYSE listing to the Texas Stock Exchange (TXSE), effective October 2–5, 2026. Although voluntary and not a failure to satisfy listing standards, this transfer of listing from a major national exchange to a regional exchange is a material event affecting the registrant's public market visibility and liquidity profile.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-09-10
Item 8.01
GeoVax received a delisting determination from Nasdaq on August 27, 2026, for failure to meet the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The company has requested a hearing before the Nasdaq Hearings Panel scheduled for October 13, 2026, to appeal the delisting determination. The filing explicitly addresses the delisting risk and the company's plan to regain compliance with Nasdaq listing standards, which is a material event affecting the registrant's continued listing status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 85%
filed 2026-09-10
The filing discloses that Tevogen regained compliance with Nasdaq's $15 million minimum market value of publicly held shares requirement under Listing Rule 5450(b)(2&3)(C), resolving a prior delisting risk. While the resolution is positive, the disclosure itself documents a material listing compliance matter that would affect investor assessment of the company's continued exchange listing status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-09-10
The filing discloses Item 3.01 regarding a Nasdaq delisting notice. The Company received written notice on August 20, 2026 that it failed to timely file its Form 10-Q for the period ended June 30, 2026, triggering non-compliance with Nasdaq Listing Rule 5250(c)(1). Although the Company subsequently regained compliance by filing the Form 10-Q on September 9, 2026, the core event reported is the delisting risk and notice of failure to satisfy a continued listing rule, which is material to investors.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-09-10
Item 3.01
USA Compression Partners voluntarily transferred its common units' listing from the New York Stock Exchange to the Texas Stock Exchange, effective October 2–5, 2026. This material change in listing venue affects trading liquidity, investor access, and market visibility.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 94%
filed 2026-09-10
Item 3.01
Sunoco LP voluntarily withdrew its Common Units from listing on the NYSE and transferred the listing to the TXSE, effective October 2–5, 2026. Although voluntary rather than forced, this transfer from a major national exchange to a regional exchange represents a material change in trading venue, liquidity, and investor accessibility.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 94%
filed 2026-09-10
Item 3.01
SunocoCorp LLC voluntarily transferred the listing of its Common Units from the NYSE to the TXSE, effective October 2–5, 2026. The units ceased trading on NYSE at market close on October 2, 2026, and began trading on TXSE on October 5, 2026. Although voluntary rather than involuntary, this transfer of listing materially affects liquidity, trading venue, and market accessibility for the security.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-09-09
EX-99.1
The exhibit announces that XCHG Limited has regained compliance with Nasdaq's minimum bid price requirement (Nasdaq Listing Rule 5450(a)(1)) after previously falling out of compliance on June 24, 2026. The company's stock price had fallen below $1.00 per ADS for 30 consecutive business days, triggering a 180-day cure period. The announcement confirms the company has now satisfied the requirement with 10 consecutive business days at or above $1.00 per ADS, closing the deficiency matter. This is a material delisting-risk disclosure because it directly addresses the company's continued listing status on Nasdaq and the resolution of a compliance failure that could have resulted in delisting.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-09-09
EX-99.1
Premium Catering received a Nasdaq Delinquency Letter dated September 4, 2026, notifying the company that it failed to timely file its interim report on Form 6-K for the fiscal half year ended December 31, 2025, in violation of NASDAQ Listing Rule 5250(c)(1). The company has 60 days to submit a compliance plan and 180 days from the due date (December 28, 2026) to regain compliance; failure to do so will result in delisting of its Class A ordinary shares from NASDAQ. This is a direct notice of non-compliance with continued listing requirements and explicit delisting risk.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-09-09
The 8-K discloses Iveda's receipt of a Nasdaq notice granting an additional 180-calendar-day compliance period (through March 1, 2027) to regain the minimum $1.00 bid price requirement under Listing Rule 5550(a)(2). The company previously received a deficiency notice on March 6, 2026, and failed to cure during the initial 180-day period. This is a classic delisting-risk disclosure under Item 3.01, with explicit language that "If compliance cannot be demonstrated by March 1, 2027, Nasdaq will provide written notification that the Company's securities will be delisted" and acknowledgment that "there can be no assurance that the Company would appeal Nasdaq's delisting determination or that such an appeal would be successful."
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-09-09
Item 8.01
The filing discloses that GameSquare regained compliance with Nasdaq Listing Rule 5550(a)(2) after previously receiving a deficiency notice on September 10, 2025, for failing to maintain the $1.00 minimum bid price requirement. While the current disclosure is positive (regaining compliance), the substance of the Item 8.01 disclosure centers on the company's delisting risk status and its resolution. This is a material event affecting the registrant's continued listing eligibility.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-09-09
The filing discloses that bioAffinity Technologies received notice from Nasdaq on July 30, 2026, that it had failed to maintain the minimum bid price of $1.00 per share required under Nasdaq Listing Rule 5550(a)(2), and was therefore not in compliance with continued listing requirements. Although the company subsequently regained compliance by September 8, 2026 (as confirmed in the Written Notice), the core event disclosed is the delisting risk and the company's appeal process to avoid delisting. This is material to investors as it directly affects the company's ability to remain listed on Nasdaq.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-09-09
Item 8.01
The disclosure announces a 1-for-80 reverse stock split explicitly "intended to help the Company regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market." This is a direct response to delisting risk—the company is taking corrective action to avoid loss of listing. While the reverse split itself is a capital structure event, the material trigger and disclosure focus is the underlying delisting compliance issue, making this a delisting_risk classification.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-09-09
EX-99.1
The exhibit is a Form 51-102F3 Material Change Report announcing NuRAN Wireless's voluntary delisting from the Canadian Securities Exchange (CSE), effective September 4, 2026. The press release explicitly states "NuRAN Wireless Announces Plans to Voluntarily Delist from the Canadian Securities Exchange" and confirms that "the close of business on September 4, 2026, will be the final trading day for NuRAN on the CSE." This is a material change affecting the registrant's listing status, though characterized as voluntary rather than involuntary delisting risk. The exhibit also discloses a director resignation (Navindran Naidoo), but the primary material event is the delisting announcement.
View raw filing on EDGAR →